Abstract:A ferroptosis and pyroptosis co‐activated nanomodulator is constructed to reverse the immunosuppressive tumor microenvironment for "cold" tumor immunotherapy and lung metastasis suppression, accomplished by the promoted dendritic cells maturation and cytotoxic T lymphocytes elevation in tumors for the release of massive tumor‐associated antigens. Immune checkpoint blockade (ICB) therapy is an emerging strategy for cancer immunotherapy; however, the actual effects of ICB therapy are greatly limited by the immunosuppressive tumor microenvironment (TME, i.e., "cold" tumors). Although engineered nanomaterials display significant importance to regulate TME in cancer treatment, most of them focus on "immunosilent" apoptotic processes that cannot elicit sufficient immune responses for further immunotherapy. Herein, a GSH‐responsive nanomodulator is reported that can reverse the immunosuppressive TME for "cold" tumor immunotherapy and lung metastasis inhibition through simultaneous ferroptosis and pyroptosis induction. The nanomodulator is constructed by loading FDA‐approved sulfasalazine (SAS) and doxorubicin (DOX) on disulfide‐doped organosilica hybrid micelles, where SAS and DOX are released through the GSH‐stimulated rupture of micelles to induce ferroptosis and pyroptosis, respectively, promoting dendritic cells (DCs) maturation and cytotoxic T lymphocytes (CTLs) elevation through massive tumor‐associated antigen release. In vivo experimental results verify that desirable tumor destruction of the nanomodulator at low concentrations is achieved. More importantly, combination of this nanomodulator and programed death ligand‐1 antibodies significantly inhibits primary tumors and distant lung metastases as a result of elevated mature DCs and CTLs. This strategy to modulate immunosuppressive TME by nanomodulator‐induced non‐apoptotic death provides a new promising paradigm for ICB therapy.

GSH Depletion-Induced Activation of Dimersomes for Potentiating the Ferroptosis and Immunotherapy of "Cold" Tumor.

Dual GSH-exhausting Sorafenib Loaded Manganese-Silica Nanodrugs for Inducing the Ferroptosis of Hepatocellular Carcinoma Cells.

Targeted Gsh-Exhausting And Hydroxyl Radical Self-Producing Manganese-Silica Nanomissiles For Mri Guided Ferroptotic Cancer Therapy

Chemodynamic therapy combined with endogenous ferroptosis based on "sea urchin-like" copper sulfide hydrogel for enhancing anti-tumor efficacy

Enhanced ferroptosis therapy with a "nano-destructor" by disrupting intracellular redox and iron homeostasis

A ferroptosis-reinforced nanocatalyst enhances chemodynamic therapy through dual H2O2 production and oxidative stress amplification

Novel Carbon Quantum Dots Precisely Trigger Ferroptosis in Cancer Cells Through Antioxidant Inhibition Synergistic Nanocatalytic Activity.

Bioactive Iridium Nanoclusters with Glutathione Depletion Ability for Enhanced Sonodynamic-Triggered Ferroptosis-Like Cancer Cell Death

GSH/Ph Dual Activatable Crosslinked And Fluorinated Pei for Cancer Gene Therapy Through Endogenous Iron De‐Hijacking And in Situ Ros Amplification

Amorphous Ultra‐small Fe‐based Nanocluster Engineered and ICG Loaded Organo‐mesoporous Silica for GSH Depletion and Photothermal‐Chemodynamic Synergistic Therapy

Self‐Assembled Copper‐Based Nanoparticles for Glutathione Activated and Enzymatic Cascade‐Enhanced Ferroptosis and Immunotherapy in Cancer Treatment

Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.

Ferroptosis and Pyroptosis Co‐Activated Nanomodulator for "Cold" Tumor Immunotherapy and Lung Metastasis Inhibition

Multifunctional Tumor-Targeting Carbon Dots for Tumor Microenvironment Activated Ferroptosis and Immunotherapy in Cancer Treatment

Biodegradable Nanotherapeutic with Simultaneously GSH Depletion and H2O2 Supplying for Enhanced Synergistic Chemotherapy/chemodynamic Therapy

Biomimetic Nanoarchitectonics with Chitosan Nanogels for Collaborative Induction of Ferroptosis and Anticancer Immunity for Cancer Therapy

Photothermal-Enhanced Inactivation of Glutathione Peroxidase for Ferroptosis Sensitized by an Autophagy Promotor

Hijacking Endogenous Iron and GSH Via a Polyvalent Ferroptosis Agonist to Enhance Tumor Immunotherapy

A strategy of "adding fuel to the flames" enables a self-accelerating cycle of ferroptosis-cuproptosis for potent antitumor therapy

Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer

Drug-independent NADPH-consuming micelles collaborate with ROS-generator for cascade ferroptosis amplification by impairing redox homeostasis